Clinical Trial Update: Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma [Phase 4]

View source ↗

Summary

This document reports a Phase 4 clinical trial update for a secondary infusion of Relma-cel in relapsed or refractory B-cell lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Lymphoma

Drugs mentioned

• Relma-cel Injection

Snippet

Sponsor: Ruijin Hospital | Conditions: Relapsed or Refractory B-cell Lymphoma | Phase 4 | Status: RECRUITING